Peptic ulcer is the most common cause of upper-GI bleeding (UGIB). Despite the advances in the management of this condition, mortality remains significant, at 10%.[@bib1] Hemospray (TC-325, Cook Medical, Bloomington, Ind) is a new hemostatic modality that has shown interesting results in a variety of causes, either as monotherapy or as rescue therapy,[@bib2] apparently with the advantage of its easy applicability, especially in difficult situations. Hemospray consists of a mineral powder that absorbs water when applied into the actively bleeding lesion, forming a mechanical barrier over the bleeding site.[@bib3]

A 58-year-old man experienced major in-hospital UGIB. The patient did not describe previous diseases and presented to the emergency department with progressive dyspnea. A CT scan showed small nodules uniformly distributed throughout both lungs, suggesting miliary tuberculosis associated with pneumonia. Broad-spectrum antibiotics were initiated. Four days later, the patient was seen with massive hematochezia and hemodynamic instability requiring vasoactive drugs and ventilatory support. Pharmacologic treatment included a proton pump inhibitor, 80 mg/d. Endoscopic evaluation was done promptly and showed a large bulbar ulcer with an adherent clot without active bleeding ([Fig. 1](#fig1){ref-type="fig"}A). Epinephrine-hypertonic glucose solution (1:10,000) injection was performed with a 23-gauge sclerotherapy needle to prevent rebleeding. A total of 2 mL was injected per puncture. As the needle was extracted after the third puncture, spurting bleeding was seen ([Fig. 1](#fig1){ref-type="fig"}B) and was treated successfully with Hemospray ([Figs. 1](#fig1){ref-type="fig"}C and D). The powder was sprayed through a 7F catheter in short bursts (1-2 seconds). The tip of the catheter should remain at a certain distance of the bleeding site (1-2 cm). The therapy was performed until no further bleeding was seen. Hemodynamic stability was achieved during the following hours, and both vasoactive drugs and mechanical ventilation were withdrawn. Second-look endoscopy evidenced adequate hemostasis. No other GI bleeding was reported in the following 30 days.Figure 1**A,** Bulbar ulcer with adherent clot. **B,** Ulcer with active bleeding. **C,** Hemospray therapy. **D,** Final aspect of hemostatic treatment.

Hematochezia is not the most common presentation of UGIB; however, it indicates severe bleeding and is related to worse outcomes, including mortality.[@bib4] The decision to treat ulcers with adherent clot is based on the medical literature,[@bib5] and this report strengthens this need because the patient would probably have experienced rebleeding and a bad outcome if the physician had used only pharmacologic treatment. Our impressions of Hemospray are very positive based on our early experiences. This video shows successful treatment of a massive bleeding ulcer ([Video 1](#appsec1){ref-type="sec"}, available online at [www.VideoGIE.org](http://www.videogie.org){#intref0015}). Recently, a large, multicenter trial was published and enrolled 202 patients with UGIB who received Hemospray therapy.[@bib6] These multicenter data confirmed the high rate of immediate hemostasis (96.5%), excellent feasibility, and good safety profile of Hemospray.
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Written transcript of the video audio is available online at [www.VideoGIE.org](http://www.VideoGIE.org){#intref0010}.
